[Injection aids for intermediate-term acting insulin. Experiences with the OptiPen].
Twenty diabetics conventionally treated with Depot H and/or Basal H Insulin Hoechst received the OptiPen as an injection aid for the corresponding U100 insulin preparations. Seventeen patients had such a positive opinion of the pen, that they wanted to continue using it. After 15.6 +/- 5.3 weeks of "pen therapy", the mean insulin dose remained unchanged. In the 14 patients who had been treated with insulin long before the change over to the pen, the mean HbA1 level showed no change (8.8 +/- 1.2% before versus 8.7 +/- 1.5% under pen therapy). The use of an injection aid--in this case the OptiPen--facilitates insulin therapy for the usually older diabetics treated with intermediate acting or mixed insulin, too. Technical problems over the long term were not encountered and the quality of metabolic control remained unchanged.
Schifferdecker
E
E
Jungmann
E
E
Schöffling
K
K
D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D008875:Middle Aged
D003692:Delayed-Action Preparations
Injektionshilfen für mittellang wirkende Insuline. Erfahrungen mit dem OptiPen.